Intra-Cellular Therapies, Inc.

    Jurisdiction
    United States
    LEI
    5299002U2KGF193IJA20
    ISIN
    US46116X1019 (ITCI)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    45 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Read full profile

    Fundamentals

    Net revenue
    €580.55M
    Gross margin
    91.6%
    EBIT
    -€99.56M
    EBIT margin
    -17.1%
    Net income
    -€63.69M
    Net margin
    -11.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €800.88M +38.0% €15.52M -124.4%
    €1.31B +63.0% €433.75M +2,695.7%
    €1.86B +42.6% €851.11M +96.2%

    Products

    Product Revenue
    Product €680.50M 117.2%
    Grant €351.00K 0.1%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Congress transactions

    Name Transaction date Value
    Josh Gottheimer May 14, 2025 $1.00K–$15.00K
    Gilbert Cisneros May 6, 2025 $1.00K–$15.00K
    Josh Gottheimer April 10, 2025 $1.00K–$15.00K
    Gilbert Cisneros April 7, 2025 $1.00K–$15.00K
    Josh Gottheimer February 10, 2025 $1.00K–$15.00K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 621K $81.95M +307K Buy
    George Soros 117K $15.38M +2.6K Buy

    Earnings Calls

    Latest earnings call: May 7, 2024 (Q1 2024)

    Add to watchlist

    Notifications